Bilirubin is not associated with urinary bladder cancer risk and prognosis: A Mendelian Randomization Study in the UK Biobank

Nadezda Lipunova* ^{1,2,3}, Richard T Bryan¹, Maurice Zeegers ^{1,2}

¹Institute of Cancer and Genomic Sciences, University of Birmingham, United Kingdom

²Department of Complex Genetics, Care and Public Health Research Institute, School for Nutrition and Translational Research in Metabolism, Maastricht University, The Netherlands

³Centre for Computational Biology, University of Birmingham, United Kingdom

Correspondence Address:

Nadezda Lipunova

Institute of Cancer and Genomic Sciences,

University of Birmingham,

United Kingdom, B15 2TT

Email: nxl689@student.bham.ac.uk

n.lipunova@maastrichtuniversity.nl

Tel. Nr.: +44029189097

Number of words in Abstract: 198

Number of words in the main text: 1,827

Running Title: Bilirubin and Bladder Cancer Risk

Keywords: bilirubin, bladder cancer, risk, prognosis, Mendelian Randomization

33 **ABSTRACT**

34 **Background**

35 Mutations in *UGT1A* gene have been associated with the development and prognosis of
 36 urinary bladder cancer (UBC). UGT1A proteins are involved in a spectrum of detoxification
 37 processes, hence the biological mechanism between *UGT1A* and UBC is difficult to
 38 elucidate. Concurrently, mild hyperbilirubinemia, caused by alterations in *UGT1A*, has been
 39 associated with multiple health outcomes. We have investigated the potential effect of mild
 40 hyperbilirubinemia on UBC risk and prognosis, using a Mendelian Randomization (MR)
 41 approach in the UK Biobank.

42 **Methods**

43 Data on 1,281 UBC patients and 4,071 controls was available for a two-stage least squares
 44 MR estimation with rs6742078 as an instrumental variable. First, linear regression was fitted
 45 to establish the relationship between the rs6742078 and bilirubin levels (total and
 46 unconjugated). Secondly, bilirubin values were used to predict tested outcomes under a
 47 logistic model. Both stages were adjusted for participant sex, smoking status, and age.

48 **Results**

49 MR analysis showed no significant effects of bilirubin levels on UBC risk (total bilirubin:
 50 OR=1.02, 95% CI: 0.99-1.04; unconjugated bilirubin: OR=1.02, 95% CI: 0.99-1.05). No effects
 51 were observed for events of UBC recurrence, progression, or survival.

52 **Conclusion**

53 Our study suggests mild hyperbilirubinemia is not associated with urinary bladder cancer
 54 risk and prognosis.

55 INTRODUCTION

56 Urinary bladder cancer (UBC) poses a great burden for patients and healthcare systems, but
57 the clinical management has seen little change over the last few decades [1, 2]. Genetic
58 discoveries are a useful tool for investigating UBC development and enhance patient care.
59 However, elucidating the biological mechanisms behind the effect of genetics that would
60 help identify clinical targets offers a challenge.

61 Previous studies have identified the relevance of single nucleotide polymorphisms (SNPs) in
62 the *UGT1A* gene in UBC development, namely rs11892031 [3], rs17863783 [4], and
63 rs7571337 [5]. Moreover, reports for *UGT1A* effects being modified by smoking [6] is
64 especially relevant for the smoking population, as impaired metabolite clearance may result
65 in a longer exposure to tobacco-related carcinogens. Importantly, the evidence is lacking
66 whether *UGT1A* mutations are also relevant for UBC prognosis. One study assessing SNPs in
67 *UGT1A* (rs11892031 and rs17863783) for UBC prognosis did not find any significant results
68 [7].

69 Interestingly, a mutation in the *UGT1A*28* locus is a principal cause for Gilbert's syndrome
70 (GS). GS is a benign condition with global prevalence of about 5-10%, clinically present as
71 mildly elevated bilirubinaemia [8, 9]. Among affected, the expression of the bilirubin UDP-
72 glucuronosyltransferase (UGT) is reduced to about 30% of normal hepatic glucuronidating
73 activity [10, 11]. Rs6742078, located close to the *UGT1A*28* TATA box polymorphism was
74 found to explain roughly 18% of the total serum bilirubin and can be used as a proxy in
75 genetic analyses [12].

76 Mildly elevated bilirubinaemia has been associated with various health outcomes,
77 specifically protection against heart disease, diabetes, and overall mortality [9, 13]. It is
78 difficult to establish whether hyperbilirubinemia is the actual causal agent for these benefits
79 or merely a correlated marker, but the use of Mendelian Randomization (MR) makes it
80 possible to decipher its' role in human health. MR studies on bilirubinaemia and
81 cardiovascular disease [14], stroke [15], and non-fatty liver disease [16] showed bilirubin is
82 unlikely to play a role in these traits. On the other hand, a report on diabetes risk indicates
83 increased bilirubin levels exhibit a protective effect [17]. It has to be noted most MR studies
84 (with the exception of Luo *et al.* [16]) have only considered total serum bilirubin (TB) levels.
85 Instead, high TB levels may reflect impaired liver function, and hence only unconjugated
86 bilirubin (UB) is hypothesized to offer health benefits, if any [9].

Despite *UGT1A* being associated with bladder cancer, the potential effect of mild hyperbilirubinemia on UBC risk and outcomes have not yet been assessed. In the current MR study, we aimed to investigate the association between TB and UB serum levels and the risk of developing UBC, as well as UBC prognosis (recurrence, progression, and survival) in the UK Biobank cohort [18, 19].

92

93 **METHODS**

94 **Study population**

95 UK Biobank is one of the largest population-based cohorts in the UK. Genetic and clinical
96 data is collected for over 500,000 participants, aged 40-69 at the time of recruitment (2006-
97 2010). Detailed descriptions on UK Biobank design, data collection, and processing are
98 described in detail elsewhere [18, 19]. For the analysis on UBC prognosis, the sample was
99 limited to UBC patients only (International Classification of Diseases (ICD) codes of C67.0,
100 C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, D09.0 (ICD10) and 1880, 1882,
101 1884, 1886, 1888, 1889, 2337 (ICD9).

102 For analyses on UBC risk, a random sample of 5000 participants were drawn as controls.

103 After data cleaning procedures, there were 1,281 UBC patients and 4,071 controls with
104 clinical and genetic data available for analysis.

105 **SNP selection**

106 Rs6742078 was chosen as the instrumental variable (IV) for bilirubin levels. Rs6742078
107 shows high correlation ($r^2 > 0.8$) with the causative locus for GS and has been successfully
108 used for other MR studies on various phenotypes [15, 16, 17].

109 **Outcomes and exposures**

110 The overall risk of developing UBC was treated as a binary outcome.

111 Death was modelled as an overall (death vs no death) or a UBC-specific event (death vs no
112 death, when primary cause of death was assigned C67- (ICD10) or 188-related (ICD9) codes).

113 Prognostic endpoints (recurrence, progression) were modelled using data from Hospital
114 Episode Statistics (HES) and Death Registry data.

115 For recurrence, three conditions to be representative of an event. First, a transurethral
116 resection of a bladder tumour (TURBT) (OPCS4 code M42) is regarded to be enough to
117 signify a UBC event. Secondly, a time period longer than 4 months between
118 chemotherapeutic treatments into urinary bladder (OPCS4 codes M494/M495) was

considered to be substantial to correspond to two independent events. Thirdly, a UBC diagnosis if an examination of the urinary bladder (OPCS4 code M45) was led by a relevant intervention within 6 months. Relevant interventions were chemotherapeutic treatments into urinary bladder, cystectomy, radiotherapy, and chemotherapy (OPCS4 codes of M494/M495; M34; X65; X72; X292, X298, X308, X352, respectively).

UBC progression was considered to have taken place if either a TURBT (OPCS4 code M42) or examination of the urinary bladder (OPCS4 code M45) was followed by interventions of cystectomy (OPCS4 code M34) and/or radiotherapy (OPCS4 code X65) within 6 months.

Two recurrence and/or progression events were considered independent of one another if time in between the records was greater than 3 months.

Bilirubin levels (micromoles per litre, $\mu\text{mol/L}$) have been measured in the UK Biobank by photometric colour analysis on a Beckman Coulter AU5800.

Ethics and consent

All UK Biobank participants have provided informed consent. Current research has been conducted using the UK Biobank Resource under Application Number 42772.

Genotype data quality control (QC) and imputation

Detailed QC procedures on imputation in the UK Biobank are described elsewhere [19]. Our analyses were restricted White British participants to avoid population stratification bias [19].

Statistical analysis

F statistic was calculated to establish the instrument strength for our analyses [20]. The rule of thumb is to consider an instrument acceptable if the F statistic is >10 [20].

Firstly, have tested the association between TB and UB levels with the following outcomes: UBC risk, death, recurrence, and progression. For all analyses, logistic regression was fitted while adjusting for participant sex, smoking status (ever vs never), and age at the time of diagnosis (or recruitment for controls).

Secondly, we have used a two-stage least squares (2SLS) MR estimation on all outcomes with rs6742078 as an IV. In the first stage, linear regression was fitted to establish the relationship between the IV and bilirubin levels (separately for TB and UB) assuming an additive model of inheritance. The value of bilirubin from the first step was used to predict UBC outcomes in the second stage under a logistic model. Both stages were adjusted for participant sex, smoking status (ever vs never), and age.

The difference between baseline characteristics between cases and controls was tested using Chi-square for categorical variables and t-test for continuous outcomes. Statistical significance was assumed at two-tailed $p < 0.05$ throughout the analysis.

RESULTS

The rs6742078 proved to be a valid instrument for the analyses, as the F statistic has been calculated as 1,701 for TB and 1,751 for UB (both $p < 0.001$).

Baseline characteristics of the cases and controls are presented in **Table 1**. UBC cases were significantly older (mean age=61.3 years) than the controls (mean age=57.4 years), and were more often male (cases=81.2%, controls=49.8%) as well as having history of smoking (cases=68.4%, controls=45.7%). However, bilirubin levels and rs6742028 status were comparable between bladder cancer patients and controls (TB among cases=9.92 $\mu\text{mol/L}$, TB among controls=9.66 $\mu\text{mol/L}$, $p = 0.07$; Chi-square p value for independence of rs6742028 genotype between cases and controls was 0.52).

Table 1. Descriptive characteristic of bladder cancer patients and controls in the UK Biobank.

Variables	Controls (N=4,071)	UBC Cases (N=1,281)	p value
Age (mean years, SD)	57.4 (8.06)	61.3 (8.98)	<0.001
Sex			<0.001
Males (N, %)	2029 (49.8)	1040 (81.2)	
Females (N, %)	2042 (50.2)	241 (18.8)	
Smoking status			<0.001
Never (N, %)	2209 (54.3)	405 (31.6)	
Ever (N, %)	1862 (45.7)	876 (68.4)	
rs6742028 status			0.52
GG (N, %)	1796 (44.1)	575 (44.9)	
TG (N, %)	1801 (44.3)	546 (42.6)	
TT (N, %)	474 (11.6)	160 (12.5)	
Total bilirubin ($\mu\text{mol/L}$)	9.66 (4.28)	9.92 (4.51)	0.07
Unconjugated bilirubin ($\mu\text{mol/L}$)	7.86 (3.59)	8.02 (3.79)	0.18
NMIBC	NA	1181 (92.2)	NA
Recurrence	NA	512 (40.0)	NA
Progression	NA	50 (3.90)	NA
Death	NA	176 (13.7)	NA

For the subgroup analyses within the UBC cases, there were 512 recurrence, 50 progression, and 176 death events. Non-muscle-invasive bladder cancer (NMIBC) comprised a total of 1,181 out of 1,281 UBC cases.

A multivariable-adjusted model for testing the effect of TB on overall UBC risk resulted in an odds ratio (OR) of 0.99 (95% confidence interval (CI): 0.98-1.01, $p=0.43$) (**Table 2**). The estimate was equivalent for UB (OR=0.99, 95% CI:0.97-1.01, $p=0.36$). For the events of UBC recurrence, progression, and death, both TB and UB have indicated neutral effects with all ORs being close to 1 (**Table 2**).

In the MR analysis on UBC risk, causal OR estimates were identical for TB and UB levels (TB: 1.02, 95% CI: 0.99-1.04, $p=0.18$; UB: 1.02, 95% CI: 0.99-1.05, $p=0.18$) (**Table 2**).

In the additional analyses on clinically-relevant phenotypes of NMIBC recurrence, progression, and muscle-invasive bladder cancer (MIBC) death, no association was observed in either observational model or MR analysis (data not shown).

DISCUSSION

In the current study, we have investigated the causal role of TB and UB in the development of bladder cancer, as well as UBC prognosis. Rs6742028 showed to be a valid instrument for estimating causality, however no association was observed with any of the tested outcomes.

Mutations in the *UGT1A* cluster, located in 2q37.1, have been associated with UBC in previous genetic studies [3, 4, 21, 22]. SNPs in *UGT1A* have shown both harmful [21] and protective effects for the risk of developing *de novo* UBC [4, 22], but there is uncertainty if *UGT1A* influences the disease course, especially in NMIBC. Lacombe *et al* evaluated the effect of *UGT1A1**28 SNP rs8175347 in a group of 189 NMIBC cases [23] and concluded that it significantly increased the risk of recurrence, with a gene-smoking interaction present (higher recurrence risk for ever smokers). Nevertheless, the many strata in the study resulted in small subgroup sample sizes [23]; therefore, the findings must be replicated in other cohorts to establish validity.

The UGTs, coded by the region, are involved in various processes of detoxification. Until now, the most common hypothesis suggests that variations in the activity of UGTs may confer to an altered speed and efficiency of carcinogen clearance, and thus have a role in cancer development[24]. In fact, a mapping study of the T allele of rs17863783 has been shown it results in an increased mRNA expression of the UGT1A6 in human liver tissue cells[4]. As such, it is hypothesized increased UGT1A6 function helps to facilitate faster removal of carcinogens from the bladder epithelium[4, 6, 24].

However, the UGTs may have more than one mode of action, due to a variety of function. Given that mild hyperbilirubinemia has been implicated to play a role in many conditions, it was useful to investigate whether the alterations in *UGT1A*28*, resulting high blood concentrations of bilirubin may also have an effect on UBC development and prognosis. However, our study suggests such effects are unlikely and tobacco-related carcinogen detoxification remains the most likely hypothesis for explaining the effect of *UGT1A* mutations on UBC.

We acknowledge our study carries important limitations. First, prognostic events have been modelled using an algorithm that makes use of HES, but none of the events have been confirmed on a case-by-case basis. Moreover, some events had low sample sizes (e.g. progression), and likely underpowered to detect an existing association.

CONCLUSIONS

To summarise, we have investigated the potential role of mild hyperbilirubinemia in UBC risk and prognosis. Using an MR methods for estimating causal relationships, our study suggests *UGT1A* locus contributes to bladder cancer via mechanisms other than elevated bilirubin.

220 **Table 2. Mendelian randomization analysis for bilirubin and urinary bladder cancer risk and prognosis in the UK Biobank.**

	TOTAL BILIRUBIN						UNCONJUGATED BILIRUBIN					
	Multivariable adjusted model*			Mendelian Randomization Analysis			Multivariable adjusted model*			Mendelian Randomization Analysis		
	OR	95% CI	p value	OR	95% CI	p value	OR	95% CI	p value	OR	95% CI	p value
UBC Risk	0.99	0.98-1.01	0.43	1.02	0.99-1.04	0.18	0.99	0.97-1.01	0.36	1.02	0.99-1.05	0.18
UBC Recurrence	0.99	0.97-1.02	0.58	1.00	0.96-1.05	0.98	0.99	0.96-1.02	0.60	1.00	0.95-1.05	0.98
UBC Progression	1.01	0.95-1.07	0.66	0.96	0.84-1.08	0.57	1.02	0.95-1.08	0.57	0.99	0.81-1.10	0.57
UBC Death	0.98	0.94-1.02	0.29	0.99	0.92-1.05	0.70	0.97	0.92-1.02	0.22	0.99	0.91-1.06	0.70

UBC-urinary bladder cancer; OR-odds ratio; CI-confidence interval,

*Adjusted for participant sex, age, and smoking status (ever vs never).

221 **Additional information:**

222 **Ethics Approval and consent to participate:** All procedures performed in studies involving
223 human participants were in accordance with the ethical standards of the institutional
224 and/or national research committee and with the 1964 Helsinki declaration and its later
225 amendments, or comparable ethical standards. Informed Consent: Informed consent was
226 obtained from all individual participants included in the study.

227 **Data availability**

228 UK Biobank data are available through a procedure described at
229 <http://www.ukbiobank.ac.uk/using-the-resource/>.

230 **Conflict of Interest:** The authors declare they have no conflict of interest.

231 **Funding:** No funding to declare.

232 **Author Contribution Statement:** NL designed and carried out the study and wrote the main
233 manuscript; RBT, MZ, and NL have reviewed the manuscript.

234

235 Table legends:

236 Table 1. Descriptive characteristic of bladder cancer patients and controls in the UK Biobank

237 Table 2. Mendelian randomization analysis for bilirubin and urinary bladder cancer risk and
238 prognosis in the UK Biobank.

REFERENCES

1. Park JC, Hahn NM. Bladder cancer: a disease ripe for major advances. *Clinical advances in hematology & oncology : H&O*. 2014;12(12):838-45.
2. Berdik C. Unlocking bladder cancer. *Nature*. 2017;551(7679):S34-s5.
3. Rothman N, Garcia-Closas M, Chatterjee N, Malats N, Wu X, Figueroa JD, *et al*. A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. *Nature genetics*. 2010;42(11):978-84.
4. Tang W, Fu YP, Figueroa JD, Malats N, Garcia-Closas M, Chatterjee N, *et al*. Mapping of the UGT1A locus identifies an uncommon coding variant that affects mRNA expression and protects from bladder cancer. *Hum Mol Genet*. 2012;21(8):1918-30.
5. Wang J, Wu X, Kamat A, Barton Grossman H, Dinney CP, Lin J. Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. *British journal of cancer*. 2013;108(11):2372-80.
6. Garcia-Closas M, Rothman N, Figueroa JD, Prokunina-Olsson L, Han SS, Baris D, *et al*. Common genetic polymorphisms modify the effect of smoking on absolute risk of bladder cancer. *Cancer Res*. 2013;73(7):2211-20.
7. Grotenhuis AJ, Dudek AM, Verhaegh GW, Witjes JA, Aben KK, van der Marel SL, *et al*. Prognostic relevance of urinary bladder cancer susceptibility loci. *PloS one*. 2014;9(2):e89164.
8. Hirschfield GM, Alexander GJ. Gilbert's syndrome: an overview for clinical biochemists. *Annals of clinical biochemistry*. 2006;43(Pt 5):340-3.
9. Wagner KH, Shiels RG, Lang CA, Seyed Khoei N, Bulmer AC. Diagnostic criteria and contributors to Gilbert's syndrome. *Critical reviews in clinical laboratory sciences*. 2018;55(2):129-39.
10. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, *et al*. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. *The New England journal of medicine*. 1995;333(18):1171-5.
11. Sugatani J. Function, genetic polymorphism, and transcriptional regulation of human UDP-glucuronosyltransferase (UGT) 1A1. *Drug metabolism and pharmacokinetics*. 2013;28(2):83-92.
12. Johnson AD, Kavousi M, Smith AV, Chen MH, Dehghan A, Aspelund T, *et al*. Genome-wide association meta-analysis for total serum bilirubin levels. *Human Molecular Genetics*. 2009;18(14):2700-10.
13. Wagner KH, Wallner M, Molzer C, Gazzin S, Bulmer AC, Tiribelli C, *et al*. Looking to the horizon: the role of bilirubin in the development and prevention of age-related chronic diseases. *Clinical science (London, England : 1979)*. 2015;129(1):1-25.
14. McArdle PF, Whitcomb BW, Tanner K, Mitchell BD, Shuldiner AR, Parsa A. Association between bilirubin and cardiovascular disease risk factors: using Mendelian randomization to assess causal inference. *BMC cardiovascular disorders*. 2012;12:16.
15. Lee SJ, Jee YH, Jung KJ, Hong S, Shin ES, Jee SH. Bilirubin and Stroke Risk Using a Mendelian Randomization Design. *Stroke*. 2017;48(5):1154-60.
16. Luo L, An P, Jia X, Yue X, Zheng S, Liu S, *et al*. Genetically Regulated Bilirubin and Risk of Non-alcoholic Fatty Liver Disease: A Mendelian Randomization Study. *Frontiers in Genetics*. 2018;9:662.
17. Abbasi A, Deetman PE, Corpeleijn E, Gansevoort RT, Gans RO, Hillege HL, *et al*. Bilirubin as a potential causal factor in type 2 diabetes risk: a Mendelian randomization study. *Diabetes*. 2015;64(4):1459-69.

286 18. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, *et al.* UK biobank: an
287 open access resource for identifying the causes of a wide range of complex diseases of
288 middle and old age. *PLoS medicine*. 2015;12(3):e1001779.
289 19. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, *et al.* The UK Biobank
290 resource with deep phenotyping and genomic data. *Nature*. 2018;562(7726):203-9.
291 20. Davies NM, Holmes MV, Davey Smith G. Reading Mendelian randomisation studies: a
292 guide, glossary, and checklist for clinicians. *BMJ (Clinical research ed)*. 2018;362:k601.
293 21. Selinski S, Lehmann ML, Blaszkewicz M, Ovsiannikov D, Moormann O, Guballa C, *et*
294 *al.* Rs11892031[A] on chromosome 2q37 in an intronic region of the UGT1A locus is
295 associated with urinary bladder cancer risk. *Arch Toxicol*. 2012;86(9):1369-78.
296 22. Zhang Y, Sun Y, Chen T, Hu H, Xie W, Qiao Z, *et al.* Genetic variations rs11892031 and
297 rs401681 are associated with bladder cancer risk in a Chinese population. *Int J Mol Sci*.
298 2014;15(11):19330-41.
299 23. Lacombe L, Fradet V, Levesque E, Pouliot F, Larue H, Bergeron A, *et al.* Phase II Drug-
300 Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive
301 Bladder Cancer: A Gene-Smoking Interaction. *Cancer prevention research (Philadelphia, Pa)*.
302 2016;9(2):189-95.
303 24. Sundararaghavan VL, Sindhwani P, Hinds TD, Jr. Glucuronidation and UGT isozymes
304 in bladder: new targets for the treatment of uroepithelial carcinomas? *Oncotarget*.
305 2017;8(2):3640-8.
306